Agenus Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Agenus, Maintains $40 Price Target
Buy Rating Affirmed for Agenus Amid Promising Colorectal Cancer Study Results
Agenus Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Agenus, Maintains $40 Price Target
Analysts Offer Insights on Healthcare Companies: Agenus (AGEN), Merus (MRUS) and Iovance Biotherapeutics (IOVA)
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Eledon Pharmaceuticals (ELDN) and Agenus (AGEN)
HC Wainwright & Co. : The Agenus (AGEN.US) rating was reaffirmed and adjusted from buy to buy, and the target price was $40.00.
Agenus Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA), Repligen (RGEN) and Agenus (AGEN)
Agenus Shares Target Cut to $5, Analyst Maintains Buy Rating
Agenus Analyst Ratings
B. Riley Securities Trims Agenus' Price Target to $5 From $6 After Model Update, Maintains Buy Rating
Buy Rating Affirmed for Agenus Amidst Promising Cancer Immunotherapy Developments and Strategic Financial Moves
Agenus Poised for Growth: Anticipated BLA Filing and Promising Clinical Data Underpin Buy Rating
Agenus Analyst Ratings
HC Wainwright & Co. Maintains Buy on Agenus, Maintains $8 Price Target
Agenus's Promising Botensilimab Leads to Buy Rating From Analyst Mayank Mamtani
Analysts Are Bullish on Top Healthcare Stocks: Agenus (AGEN), Zivo Bioscience (ZIVO)
Analysts Offer Insights on Healthcare Companies: Agenus (AGEN), Regeneron (REGN) and Warby Parker (WRBY)